Jpmorgan Chase & CO Longboard Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Longboard Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 97,995 shares of LBPH stock, worth $5.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

97,995

Previous 606,595 83.85%

Holding current value

$5.88 Million

Previous $16.4 Million 80.08%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Dec 26, 2024	SELL	$27.58 - $39.5 $14 Million - $20.1 Million	-508,600 Reduced 83.85%	97,995 $3.27 Million
Q3 2024 Nov 08, 2024	SELL	$27.58 - $39.5 $14 Million - $20.1 Million	-508,600 Reduced 83.85%	97,995 $3.27 Million
Q2 2024 Dec 26, 2024	BUY	$17.0 - $27.03 $8.65 Million - $13.7 Million	508,600 Added 519.01%	606,595 $16.4 Million
Q2 2024 Aug 12, 2024	BUY	$17.0 - $27.03 $1.72 Million - $2.74 Million	101,421 Added 20.08%	606,595 $16.4 Million
Q1 2024 Dec 26, 2024	BUY	$18.89 - $26.06 $7.69 Million - $10.6 Million	407,179 Added 415.51%	505,174 $10.9 Million
Q1 2024 May 10, 2024	SELL	$18.89 - $26.06 $558,048 - $769,864	-29,542 Reduced 5.52%	505,174 $10.9 Million
Q4 2023 Dec 26, 2024	BUY	$3.68 - $6.5 $1.61 Million - $2.84 Million	436,721 Added 445.66%	534,716 $3.22 Million
Q4 2023 Feb 12, 2024	BUY	$3.68 - $6.5 $4,467 - $7,891	1,214 Added 0.23%	534,716 $3.22 Million
Q3 2023 Nov 14, 2023	SELL	$5.49 - $7.49 $185,578 - $253,184	-33,803 Reduced 5.96%	533,502 $2.97 Million
Q2 2023 Aug 11, 2023	BUY	$4.19 - $10.05 $2.38 Million - $5.7 Million	567,305 New	567,305 $4.16 Million

Others Institutions Holding LBPH

# of Institutions

126

Shares Held

34.9M

Call Options Held

28.9K

Put Options Held

13.9K

View Full List

About Longboard Pharmaceuticals, Inc.

Ticker LBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,586,000
Market Cap $815M
Description
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...

More about LBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Longboard Pharmaceuticals, Inc. Transaction History